Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Prevnar 13
- Development stage
- Approved
- Lead developer
- Pfizer
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Prevnar 13 is a pneumococcal 13-valent conjugate vaccine used for active immunization to prevent invasive disease, pneumonia, and acute otitis media caused by Streptococcus pneumoniae. It contains saccharides from the capsular antigens of 13 different serotypes of S. pneumoniae (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F), which are individually conjugated to a non-toxic diphtheria CRM197 protein carrier. The polysaccharides are chemically activated and covalently linked to the protein carrier to form glycoconjugates. The vaccine is adsorbed on aluminum phosphate to enhance immune response.
- Brand names
- Prevnar 13Prevnar13Prevnar-13Prevenar 13Prevenar13Prevenar-13
- Other names
- Pneumococcal 13-valent Conjugate VaccinePneumococcal13-valent Conjugate VaccinePneumococcal-13-valent Conjugate VaccinePneumococcal Polysaccharide Conjugate Vaccine (Adsorbed) 13-valent
02
Targets
SpCPS1 (Streptococcus pneumoniae capsular polysaccharide serotype 1)CPS14 (Streptococcus pneumoniae capsular polysaccharide serotype 14)CPS 18C (Streptococcus pneumoniae capsular polysaccharide serotype 18C)19A CPS (Streptococcus pneumoniae serotype 19A capsular polysaccharide)CPS19F (Streptococcus pneumoniae capsular polysaccharide serotype 19F)CPS23F (Streptococcus pneumoniae capsular polysaccharide serotype 23F)PPS3 (Streptococcus pneumoniae serotype 3 capsular polysaccharide)CPS4 (Streptococcus pneumoniae capsular polysaccharide serotype 4)PPS5 (Streptococcus pneumoniae capsular polysaccharide serotype 5)6A CPS (Streptococcus pneumoniae serotype 6A capsular polysaccharide)6B CPS (Streptococcus pneumoniae serotype 6B capsular polysaccharide)7F CPS (Streptococcus pneumoniae serotype 7F capsular polysaccharide)Streptococcus pneumoniae capsular polysaccharide serotype 9V (PnPS 9V)Streptococcus pneumoniae serotype 19F capsular polysaccharide9V CPS (Streptococcus pneumoniae serotype 9V capsular polysaccharide)
Beyond the preview
Go deeper on Prevnar 13.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Prevnar 13.